Cervical

NAFC Responds to Devastating Cuts in the House FY2024 Appropriations Bill

Retrieved on: 
Wednesday, July 26, 2023
Kaiser, Workforce, Volunteering, Insurance, Bill, Senate, Religion, Education, NAFC, HHS, Hospital, HIV, Mother, Politics, Human services, Kaiser Family Foundation, Woman, National Institutes of Health, Bangladesh Technical Education Board, Organization, Child, Congress, Cervical, Patient, National Association of Free and Charitable Clinics, Mortality, Growth, National Association, Death, House, Labour, United States Department of Health and Human Services, Nursing, Birth control, Health, Breast

As a bipartisan organization committed to the health and welfare of all individuals, the NAFC recognizes the importance of fiscal responsibility.

Key Points: 
  • As a bipartisan organization committed to the health and welfare of all individuals, the NAFC recognizes the importance of fiscal responsibility.
  • However, this bill is shockingly short-sighted and will have devastating consequences that will reverberate throughout America’s healthcare system for years.
  • The House Labor-HHS Appropriations Bill sends the message that women, especially uninsured women, and women of color, are not a priority.
  • The House Labor-HHS Appropriations Bill falls short of what our citizens deserve, and we as a country must do better.

Cervical Intraepithelial Neoplasia Drug Pipeline Research Report 2023 Featuring Inovio Pharmaceuticals, Frantz Viral Therapeutics, Antiva Biosciences, Genexine, and Merck Sharp & Dohme - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 20, 2023
Health, Pharmaceutical, CIN, Artesunate, Society, Therapy, Clinical trial, NDA, Woman, Society of Gynecologic Oncology, Cervical intraepithelial neoplasia, Research, Candidiasis, E7, Discovery, E6, Gynaecology, HPV, Growth, Intraepithelial neoplasia, III, Inovio Pharmaceuticals, Human papillomavirus infection, News, Birth control, Pharmaceutical industry, Gynecologic Oncology (journal), Cervical, Phase

The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia - Pipeline Insight, 2023" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report report offers a comprehensive analysis of the current landscape and future growth prospects in the field of Cervical Intraepithelial Neoplasia.
  • This report provides a detailed overview of the pipeline for Cervical Intraepithelial Neoplasia, including profiles of over 8 companies and 10 pipeline drugs.
  • The companies which have their Cervical Intraepithelial Neoplasia drug candidates in the most advanced stage, i.e.

COMPASSIONATE CERVIX BRUSH BIOPSY DEVICES PIVOTAL FOR NCI GLOBAL "MOONSHOT" CANCER SCREENING INITIATIVE

Retrieved on: 
Tuesday, May 16, 2023
Infection, Human papillomavirus infection, Histology, Obstetrics, HIV, University of California, Irvine School of Medicine, Initiative, PAVE, Cervical cancer, Cancer, Multimedia, National Cancer Institute, Cervical, UC, Patient, Physician, Nursing, Control, Gynaecology, Gynecologic oncology, MPH, NCI, Safety, Biopsy, Birth control, Medical imaging, Medicine

ANAHEIM, Calif., May 16, 2023 /PRNewswire/ -- Histologics LLC manufactures Kylon® medical fabric sterile brush devices which use gentle friction to biopsy the outer cervix and endocervical canal.

Key Points: 
  • ANAHEIM, Calif., May 16, 2023 /PRNewswire/ -- Histologics LLC manufactures Kylon® medical fabric sterile brush devices which use gentle friction to biopsy the outer cervix and endocervical canal.
  • Over 1 million of such cervical biopsies have been performed with this technology in the USA.
  • "Clinicians want to find true cervical cancer precursors at an early treatable stage, known to be caused by infection with the Human Papilloma Virus".
  • "The histology results obtained with the Histologics' biopsy devices have been diagnostic from samples thus far in Cambodia and a cervical cancer has been already diagnosed" said Dr. Goldstein.

Seagen Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Wednesday, February 15, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Trastuzumab, Brentuximab vedotin, Carcinoma, Head, Research and development, Priority review, SITC, Lung cancer, Journal of the National Comprehensive Cancer Network, Woman, Cancer, Society, Novartis, Georgetown University Medical Center, Interim, RAS, FDA, Growth, MedStar Health, ASCO, Cervical cancer, Genetic distance, Society for Immunotherapy of Cancer, Breast cancer, PDUFA, SGN, Patient, Dean (education), Clinical trial, Accelerated approval (FDA), PDUFA date, Merck, NCCN, Cervical, Pembrolizumab, Food, Immunotherapy, Hodgkin lymphoma, ADCETRIS, Flagship Pioneering, Esophageal cancer, Inc., American Society of Clinical Oncology, Pharmaceutical industry, Birth control, Seagen, Medicine

Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Seagen Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2022.
  • “We delivered total revenue of nearly $2 billion in 2022, reflecting 25 percent growth compared to 2021 driven by strong demand for our portfolio of approved products,” said David Epstein, Chief Executive Officer of Seagen.
  • Revenues: Total revenues in the fourth quarter and year ended December 31, 2022 were $528 million and $2.0 billion, respectively, compared to $430 million and $1.6 billion for the same periods in 2021.
  • Revenues in the 2022 periods reflected higher net product sales across the Company’s commercial portfolio.

Federman & Sherwood Investigates Namaste Laboratories, LLC and ORS Hair Care

Retrieved on: 
Monday, November 21, 2022
Class Action Lawsuit, Professional Services, Legal, Olive, Sale, African Americans, Marketing, Skin, Oil, Sherwood, Woman, ORS, Brand, Maintenance, Hair, Cervical, Olive oil, Daniel Federman, Cosmetics

The law firm of Federman & Sherwood announces the investigation against Namaste Laboratories, LLC and ORS Hair Care, arising from the manufacturing, marketing, sale and distribution of ORS hair care products throughout the United States.

Key Points: 
  • The law firm of Federman & Sherwood announces the investigation against Namaste Laboratories, LLC and ORS Hair Care, arising from the manufacturing, marketing, sale and distribution of ORS hair care products throughout the United States.
  • Namaste Laboratories, LLC develops hair and skin care products for the healing and renewal of hair, skin, and body.
  • They offer an array of products including relaxers, oils, shampoos, hair crmes and more under the Brand Name ORS Haircare , since 1998.
  • They provide a wide range of hair maintenance and styling solutions for all hair types, textures and styles especially designed for African American and women of color.

NanoTomer's New Cancer Report: Early Cancer Diagnosis and Increasing Survival Rate

Retrieved on: 
Wednesday, November 23, 2022
Quality of life, Physician, Atherosclerosis, Lung, Immunology, Lymph, Angina, PI, Nuclear medicine, Therapy, Plaque, Life, Population, Diagnosis, Lymphoma, Attention, Research report, FDG, Cervical cancer, Antibody, Patient, 3D, Research, HIV disease progression rates, Radiobiology, Breast cancer, Incidence, PET/CT, CEO, Radiation, Melanoma, AD, Nursing, PETS, Phase, Death, Nature Reviews Clinical Oncology, Ageing, Cervical, Surgeon, Medical imaging, Pharmaceutical industry, Cancer

NANOTOMER, a preclinical-stage biopharmaceutical company, comments on the treatment impact of early cancer diagnosis amidst declining deaths.

Key Points: 
  • In addition, the company emphasizes the significance of Early Cancer Diagnosis for improved treatment outcomes to enhance the declining cancer deaths.
  • David Elmaleh, Founder and Chairman of NANOTOMER, identified the falling death rate from Cancer in 2022.
  • However, a Cancer diagnosis is still a traumatic event for patients and their families as one of the leading causes of death worldwide.
  • The pharmaceutical scientist and inventor David R. Elmaleh, the patent holder for FDG used in PET/CT imaging for early cancer diagnosis, explains the new development, "Early diagnosis will impact the efficacy of treatment and improve outcome.

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Retrieved on: 
Thursday, October 6, 2022
Women's health, IIA, FRA, CEO, OTC, Journal, Fertility, Term sheet, Severe acute respiratory syndrome coronavirus 2, Agreement, Company, Marketing, Letter of intent, IVF, World Health Organization, Clinical trial, HPV, Woman, Vaccine, Society, CSE, Cervical cancer, Menopause, OTCQB, Patient, LOI, Partnership, World, Health, Safety, Human papillomavirus infection, Cancer, Cervical, COVID-19, Birth control, Pharmaceutical industry, BC, EU

VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L. ("Procare Health"), of Barcelona, Spain ("Procare Health"), for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product.

Key Points: 
  • VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company")announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L.
  • Under the Term Sheet, BioVaxys will have responsibility for US regulatory approval for Papilocareand anticipates US registration as a Class II medical device.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

BioVaxys Executes Binding Term Sheet for the US Marketing & Distribution for Papilocare Gel and Oral Immunocaps

Retrieved on: 
Thursday, October 6, 2022
Women's health, IIA, FRA, CEO, OTC, Journal, Fertility, Term sheet, Severe acute respiratory syndrome coronavirus 2, Agreement, Company, Marketing, Letter of intent, IVF, World Health Organization, Clinical trial, HPV, Woman, Vaccine, Society, CSE, Cervical cancer, Menopause, OTCQB, Patient, LOI, Partnership, World, Health, Safety, Human papillomavirus infection, Cancer, Cervical, COVID-19, Birth control, Pharmaceutical industry, BC, EU

VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L. ("Procare Health"), of Barcelona, Spain ("Procare Health"), for exclusive marketing and distribution in the United States of Procare Health's leading patented product, Papilocare™, the world's first and only vaginal gel product with clinical evidences to prevent and treat HPV-dependent cervical lesions, and for Immunocaps®, an oral over-the-counter nutritional supplement that supports immune function and vaginal microbiota to help re-epithelialization of cervical lesions.  As Immunocaps® is an OTC supplement, BioVaxys anticipates that regulatory approval is not required, allowing the rapid build out of sales channels and revenue generation from the product.

Key Points: 
  • VANCOUVER, BC, Oct. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF)("BioVaxys" or "Company")announced today that it has executed a binding Term Sheet ("Term Sheet" or "Agreement") with Procare Health Iberia, S.L.
  • Under the Term Sheet, BioVaxys will have responsibility for US regulatory approval for Papilocareand anticipates US registration as a Class II medical device.
  • BioVaxys has two issued US patents, and multiple US and international patent applications related to its cancer vaccines, antiviral vaccines, and diagnostic technologies.
  • BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB:BVAXF).

Cervical Cancer Diagnostics Global Market Report 2022: Increasing Prevalence of STIs Escalates Risk & Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022
Biotechnology, Health, Oncology, Adoption, Colposcopy, Risk, Diagnosis, STI, Cervical cancer, CAGR, MRI, Chlamydia, Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome (Prevention and Control) Act, 2017, CT, Rectum, Cervicectomy, Blood, Awareness, Immunotherapy, Gonorrhea, HIV/AIDS, HPV, PET, Cervical, Smoker, Syphilis, Human papillomavirus infection, COVID-19, Magnetic resonance imaging, Medical imaging, Growth

The "Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Cancer Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global cervical cancer diagnostics market size reached US$ 7.1 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 9.9 Billion by 2027, exhibiting a CAGR of 5.7% during 2021-2027.
  • Moreover, the growing emphasis on developing low-cost and efficient testing products is anticipated to fuel the market growth.

Femasys Inc. Announces the Commercial Availability of FemCerv® for Cervical Cancer Screening and Expands Management Team

Retrieved on: 
Thursday, September 29, 2022
Risk, Communication, Safety, Woman, Twitter, Infertility, LinkedIn, Company, University, Forward-looking statement, Reproductive health, Cervical, Standard of care, Pain, Solution, Annual report, Colposcopy, NASDAQ, Tubing (recreation), GLOBE, SEC, Pharmaceutical industry, Medical imaging, Risk management, Marketing

ATLANTA, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced the commercial availability of FemCerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity that is expected to be an improvement over the existing standard of care. The Company also announced the hiring of Michael Meier as Vice President of Sales and Marketing.

Key Points: 
  • In line with developing solutions to improve the continuum of healthcare options for women, we are pleased to announce the commercial availability of FemCerv, said Kathy Lee-Sepsick, founder, president and chief executive officer of Femasys.
  • FemCerv can be used in place of these antiquated products to capture and protect a comprehensive 360-degree tissue sample in a relatively pain free office visit.
  • Ms. Lee-Sepsick also added, We are pleased to have Michael join our team at this exciting time as we broaden our commercial portfolio.
  • Mr. Meier brings over 20 years of commercial experience to the Femasys team.